365. Medicaid Spending and Health-Related Social Needs in the North Carolina Healthy Opportunities Pilots Program.
作者: Seth A Berkowitz.;Jessica Archibald.;Zhitong Yu.;Myklynn LaPoint.;Salma Ali.;Maihan B Vu.;Gaurav Dave.;Kori B Flower.;Marisa Elena Domino.
来源: JAMA. 2025年333卷12期1041-50页
Health-related social needs are drivers of worse health and high health care spending. In North Carolina Medicaid's 1115 waiver, the Healthy Opportunities Pilots (HOP) program allows for nonmedical services to address health-related social needs, such as healthy food boxes and housing navigation, financed by Medicaid, in 3 regions of North Carolina.
369. Unintentional Fentanyl Use Detected in Hair of People With HIV Risk Using Methamphetamine.
作者: Ayesha Appa.;Matthew A Spinelli.;Marjan Javanbakht.;M J Heise.;Hideaki Okochi.;Alexander R Bazazi.;Phillip Coffin.;Pamina M Gorbach.;Monica Gandhi.
来源: JAMA. 2025年333卷14期1257-9页 372. A New Legal Standard for Medical Malpractice.
Patients in the US have persistent needs for safe, evidence-based care. Physicians in the US report fear of liability risk and the need to practice "defensive medicine." In 2024, the American Law Institute revised the legal standard for assessing medical negligence. Understanding the implications of this change is crucial for balancing patient safety, physician autonomy, and the legal system's role in health care.
374. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.
作者: Xiaotian Zhang.;Jufeng Wang.;Gang Wang.;Yanqiao Zhang.;Qingxia Fan.;Chuangxin Lu.;Changlu Hu.;Meili Sun.;Yiye Wan.;Sanyuan Sun.;Junye Wang.;Li Zhang.;Yongqian Shu.;Jie Luo.;Dan Zhu.;Zhenwei Shen.;Sheng Yao.;Qingmei Shi.;Jason Yang.;Lin Shen.; .
来源: JAMA. 2025年333卷15期1305-1314页
Gastric cancer, including gastroesophageal junction cancer, is one of the most commonly diagnosed cancers worldwide, with high mortality. Sugemalimab is a fully human anti-programmed death-ligand 1 (PD-L1) antibody. The combination of sugemalimab and chemotherapy showed promising antitumor activity and safety in a phase 1b study among patients with treatment-naive, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This combination was further evaluated in the GEMSTONE-303 phase 3 trial.
|